U.S. tariffs may cause drug shortages and price increases, warns healthcare firm Novo Nordisk.

Novo Nordisk, a major healthcare company, warns that U.S. tariffs could lead to drug shortages and price hikes, especially for generic medicines. CEO Lars Fruergaard Jørgensen notes that the company sources key ingredients internationally, and tariffs could disrupt this, raising costs. The company is investing in U.S. facilities but warns that tariffs could still impact drug prices and availability.

5 weeks ago
11 Articles

Further Reading